| teriflunomide / Generic mfg. |
| Ongoing | 4 | 30 | Europe | teriflunomide, nd, Film-coated tablet, AUBAGIO - 14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 28 COMPRESSE | UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI, genzyme | RELAPSING-REMITTING MULTIPLE SCLEROSIS SCLEROSI MULTIPLA REMITTENTE RECIDIVANTE, ND ND, Diseases [C] - Nervous System Diseases [C10] | | | | |
2016-003622-16: The effect of teriflunomide on brain microglial cell activation in multiple sclerosis. |
|
|
| Ongoing | 4 | 30 | Europe | Teriflunomide, L04AA31, Film-coated tablet, AUBAGIO | Turku University Hospital, Sanofi-aventis groupe | Multiple sclerosis, MS disease, Diseases [C] - Nervous System Diseases [C10] | | | | |
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros. |
|
|
| Ongoing | 4 | 150 | Europe | Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio | Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet | Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10] | | | | |
2021-003195-13: Importance of monitoring of drugs used in the treatment of multiple sclerosis Význam terapeutického monitorování perorálně podávaných léčiv modifikující průběh choroby (“disease-modifying drugs”) užívaných k léčbě roztroušené sklerózy |
|
|
| Not yet recruiting | 4 | 800 | RoW | Aubagio 14MG TBL FLM, Mavenclad 10MG TBL NOB, Tecfidera 240MG CPS ETD, Gilenya 0,5MG CPS DUR, Tablet, Capsule, Aubagio 14MG TBL FLM, Mavenclad 10MG TBL NOB, Tecfidera 240MG CPS ETD, Gilenya 0,5MG CPS DUR | Fakultní nemocnice Ostrava, Fakultní nemocnice Ostrava | multiple sclerosis roztroušená skleróza, multiple sclerosis roztroušená skleróza, Diseases [C] - Nervous System Diseases [C10] | | | | |
2021-002810-15: Peripheral neuropathy as potential side effect in patients with multiple sclerosis treated with teriflunomide. |
|
|
| Not yet recruiting | 4 | 11 | Europe | Coated tablet, AUBAGIO 14 mg | CHU Brugmann, CHU Brugmann | Multiple sclerosis, treated with teriflunomide, Multiple sclerosis, treated with teriflunomide, Diseases [C] - Nervous System Diseases [C10] | | | | |
2022-004331-23: Monitoring of drugs used in the treatment of multiple sclerosis Sledování léčiv užívaných při léčbě roztroušené sklerózy |
|
|
| Not yet recruiting | 4 | 150 | RoW | Aubagio 14MG TBL FLM, Gilenya 0,5MG CPS DUR, Tablet, Capsule, hard, Aubagio 14MG TBL FLM, Gilenya 0,5MG CPS DUR | Fakultní nemocnice Ostrava, Fakultní nemocnice Ostrava | multiple sclerosis roztroušená skleróza, multiple sclerosis roztroušená skleróza, Diseases [C] - Nervous System Diseases [C10] | | | | |
| Active, not recruiting | 4 | 800 | Europe, US | Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod) | The Cleveland Clinic, University of Nottingham | Multiple Sclerosis, Relapsing-Remitting | 07/27 | 09/30 | | |
2018-001292-21: Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Arrêt des traitements de fond à visée immunologique chez les patients de plus de 50 ans ayant une sclérose en plaques secondairement progressive |
|
|
| Not yet recruiting | 3 | 250 | Europe | AVONEX, BETAFERON, EXTAVIA, REBIF, PLEDIGRY, COPAXONE, AUBAGIO, TECFIDERA, GILENYA, TYSABRI, IMUREL, NOVATREX, CELLCEPT, ENDOXAN, L03 AB 08, Concentrate for solution for injection, Powder for solution for injection, Solution for injection, Solution for injection in pre-filled syringe, Tablet, Capsule, Concentrate for solution for infusion | CHU de Rennes, CHU de Rennes | Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Diseases [C] - Nervous System Diseases [C10] | | | | |
TERIS, NCT03122652: Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome |
|
|
| Completed | 3 | 125 | Europe, RoW | Teriflunomide 14 MG Oral Tablet [Aubagio], Placebo Oral Tablet | Centre Hospitalier Universitaire de Nice, Genzyme, a Sanofi Company | Multiple Sclerosis | 02/19 | 10/22 | | |
| Completed | 3 | 166 | Europe, Canada, US, RoW | Teriflunomide, AUBAGIO, HMR1726, Placebo | Genzyme, a Sanofi Company | Multiple Sclerosis | 10/19 | 07/24 | | |
2015-002298-39: A national, multi-center study to evaluate the safety of long term treatment with teriflunomide 14 mg once daily in patients with a first clinical episode suggestive of multiple sclerosis in a long-term extension period. |
|
|
| Not yet recruiting | 3 | 12 | Europe | TERIFLUNOMIDE, HMR1726, Film-coated tablet, AUBAGIO | CHU de Nice, GENZYME | patient with Clinically isolated syndrome, multiple sclerosis, Diseases [C] - Nervous System Diseases [C10] | | | | |
2020-004505-32: Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of newly diagnosed relapsing multiple sclerosis (RMS) patients |
|
|
| Ongoing | 3 | 236 | Europe | ofatumumab, Glatiramer acetate, Interferon β-1b, Interferon β-1a, Peginterferon β-1a, Teriflunomide, Dimethyl fumarate, OMB157, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Powder and solution for solution for injection, Solution for injection, Solution for infusion in pre-filled syringe, Coated tablet, Gastro-resistant capsule, soft, Kesimpta | Novartis Pharma AG, Novartis Pharma AG | Multiple Sclerosis Sclérose en plaques, Multiple Sclerosis Sclérose en plaques, Diseases [C] - Nervous System Diseases [C10] | | | | |
2020-005929-89: Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinib |
|
|
| Ongoing | 3 | 800 | Europe, RoW | remibrutinib, Teriflunomide, LOU064, Film-coated tablet, Capsule, hard + tablet, Aubagio | Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Farmacéutica S.A., Novartis Pharma AG | Multiple Sclerosis, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10] | | | | |
2020-005899-36: Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinib Účinnosť a bezpečnosť remibrutinibu v porovnaní s teriflunomidom u pacientov s relabujúcou roztrúsenou sklerózou |
|
|
| Ongoing | 3 | 800 | Europe, RoW | remibrutinib, Teriflunomide, LOU064, Film-coated tablet, Capsule, hard + tablet, Aubagio | Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Farmacéutica S.A., Novartis Pharma AG | Multiple Sclerosis, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10] | | | | |
MIRANTIBUS, NCT05385744: An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis |
|
|
| Completed | 3 | 336 | RoW | BCD-132, Teriflunomide | Biocad | Multiple Sclerosis | 09/22 | 09/23 | | |
| Terminated | 3 | 1124 | Europe, Canada, US, RoW | Evobrutinib, M2951, Placebo (match to Teriflunomide), Teriflunomide, Placebo (match to Evobrutinib) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc. | Relapsing Multiple Sclerosis | 10/23 | 03/24 | | |
| Terminated | 3 | 1124 | Europe, Canada, US, RoW | Evobrutinib, M2951, Placebo (match to Teriflunomide), Teriflunomide, Placebo (match to Evobrutinib) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc. | Relapsing Multiple Sclerosis | 10/23 | 03/24 | | |
FREXALT, NCT06141473: Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis |
|
|
| Recruiting | 3 | 1400 | Europe, Canada, Japan, US, RoW | Frexalimab, Teriflunomide, Placebo infusion, Placebo tablet, MRI contrast-enhancing agents, Cholestyramine, Activated charcoal | Sanofi | Multiple Sclerosis | 05/27 | 05/27 | | |
NCT06372145: A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. |
|
|
| Recruiting | 3 | 2500 | Europe, Canada, Japan, US, RoW | Tolebrutinib, SAR442168, Placebo, Teriflunomide, Aubagio | Sanofi | Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis | 04/29 | 04/29 | | |
| Completed | 3 | 899 | Europe, Canada, US, RoW | Tolebrutinib, SAR442168, Teriflunomide HMR1726, Placebo to match Tolebrutinib, Placebo to match Teriflunomide | Sanofi | Relapsing Multiple Sclerosis | 07/24 | 07/24 | | |
GEMINI 1, NCT04410978: Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) |
|
|
| Completed | 3 | 974 | Europe, Canada, Japan, US, RoW | Tolebrutinib, SAR442168, Teriflunomide HMR1726, Placebo to match Tolebrutinib, Placebo to match Teriflunomide | Sanofi | Relapsing Multiple Sclerosis | 07/24 | 07/24 | | |
|
TWINS, NCT06663189: Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over ( : Therapies Withdrawal IN Relapsing Multiple Sclerosis) |
|
|
| Not yet recruiting | 3 | 200 | Europe | treatment withdrawal, Usual DMT continuation, MRI, Quality of Life questionnaires, Disability evaluation tests | University Hospital, Strasbourg, France, Ministry of Health, France | Relapsing-remitting Multiple Sclerosis (RRMS) | 12/26 | 05/29 | | |
| Active, not recruiting | 3 | 185 | Europe | Ofatumumab, OMB157, First line DMT, Glatiramer acetate or Interferon or Peg-Interferon beta-1a or Teriflunomide or Dimethyl fumarate or Diroximel fumarate | Novartis Pharmaceuticals, Novartis Pharma AG | Multiple Sclerosis | 10/25 | 01/26 | | |
| Active, not recruiting | 3 | 746 | Europe, US, RoW | Fenebrutinib, Teriflunomide, Placebo | Hoffmann-La Roche | Relapsing Multiple Sclerosis | 10/25 | 11/25 | | |
| Active, not recruiting | 3 | 751 | Europe, Canada, US, RoW | Fenebrutinib, Teriflunomide, Placebo | Hoffmann-La Roche | Relapsing Multiple Sclerosis | 10/25 | 11/25 | | |
| Recruiting | 3 | 800 | Europe, Canada, Japan, US, RoW | Remibrutinib, LOU064, Teriflunomide | Novartis Pharmaceuticals, Novartis Pharma AG | Relapsing Multiple Sclerosis | 04/26 | 10/30 | | |
| Recruiting | 3 | 800 | Europe, US, RoW | Remibrutinib, LOU064, Teriflunomide | Novartis Pharmaceuticals, Novartis Pharma AG | Relapsing Multiple Sclerosis | 04/26 | 10/30 | | |
| Recruiting | 2/3 | 5 | Europe | Tecfidera (BG12), Gilenya, fingolimod, Tysabri®, natalizumab, Avonex/Betaseron/Copaxone/Rebif, (Avonex®, Betaseron®, Copaxone®, Rebif®), Hematopoietic stem cell transplantation (HSCT) | Sheffield Teaching Hospitals NHS Foundation Trust | Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | 12/21 | 12/21 | | |
NCT04806737: Teriflunomide vs. Placebo During Gluten Challenge in Celiac Disease |
|
|
| Recruiting | 2a | 15 | Europe | Teriflunomide Oral Tablet, Gluten challenge | Oslo University Hospital | Celiac Disease | 08/22 | 08/22 | | |
NCT04056897: Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis |
|
|
| Active, not recruiting | 2 | 270 | RoW | BCD-132, 125 mg, Teriflunomide, Placebo, BCD-132, 500 mg | Biocad | Multiple Sclerosis | 07/20 | 12/21 | | |
2020-002307-18: A study on the efficacy and tolerability of a 14-day treatment with teriflunomide 14 mg tablets vs. placebo in subjects with well-controlled coeliac disease undergoing a 3-day gluten challenge |
|
|
| Not yet recruiting | 2 | 15 | Europe | Aubagio, Capsule, Aubagio | Oslo University Hospital, Oslo University Hospital | Coeliac disease, Coeliac disease, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT06190145: Teriflunomide for Steroid-resistant/Relapse Immune Thrombocytopenia |
|
|
| Recruiting | 2 | 40 | RoW | Teriflunomide, AUBAGIO | Peking University People's Hospital | Immune Thrombocytopenia | 10/24 | 06/25 | | |
NCT06176911: The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia |
|
|
| Recruiting | 2 | 124 | RoW | Teriflunomide, AUBAGIO, Danazol | Peking University People's Hospital, Beijing Luhe Hospital, Chinese PLA General Hospital, Navy General Hospital, Beijing, Beijing Hospital, Beijing Friendship Hospital, Peking University First Hospital, Peking University Third Hospital, China-Japan Friendship Hospital, Beijing Tsinghua Changgeng Hospital | Immune Thrombocytopenia | 12/24 | 07/25 | | |
NCT06176235: Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia |
|
|
| Recruiting | 2 | 132 | RoW | Teriflunomide, AUBAGIO, Dexamethasone | Peking University People's Hospital, Beijing Luhe Hospital, Chinese PLA General Hospital, Navy General Hospital, Beijing, Beijing Hospital, Beijing Friendship Hospital, Peking University First Hospital, Peking University Third Hospital, China-Japan Friendship Hospital, Beijing Tsinghua Changgeng Hospital | Immune Thrombocytopenia | 12/24 | 05/25 | | |
MS-tolDC_2, NCT06715605: A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded TolDC As Treatment for MS |
|
|
| Not yet recruiting | 2 | 48 | Europe | tolerogenic dendritic cells (tolDC), Standard-of-care | University Hospital, Antwerp, Hospital Germans Tríes i Pujol de Badalona | Multiple Sclerosis | 04/25 | 10/27 | | |
NCT04799288: Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis |
|
|
| Recruiting | 1/2 | 24 | US | Teriflunomide | National Institute of Neurological Disorders and Stroke (NINDS) | HAM/TSP | 08/25 | 08/25 | | |
NCT06705608: Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study |
|
|
| Completed | N/A | 4000 | NA | Fingolimod, Natalizumab, Dimethyl fumarate (DMF), Alemtuzumab, Teriflunomide | University of British Columbia | Multiple Sclerosis, Skin Cancer, Skin Cancer Melanoma, Skin Cancers - Basal Cell Carcinoma, Skin Cancer, Squamous Cell, Multiple Sclerosis (MS) - Relapsing-remitting | 12/20 | 12/20 | | |
| Recruiting | N/A | 75 | Europe | biological collection | University Hospital, Rouen | Multiple Sclerosis | 08/21 | 12/21 | | |
NCT05075499: Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab |
|
|
| Recruiting | N/A | 70 | RoW | COVID-19 vaccination, Blood withdrawn | Sheba Medical Center, Sanofi | Multiple Sclerosis | 12/21 | 09/22 | | |
| Completed | N/A | 17478 | RoW | interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab | IMPULS Endowment Fund | Multiple Sclerosis | 12/21 | 12/21 | | |
NCT05811949: Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis. |
|
|
| Completed | N/A | 52 | Europe | Dimethyl Fumarate 240 MG [Tecfidera] | IRCCS Centro Neurolesi Bonino Pulejo | Multiple Sclerosis | 10/22 | 06/23 | | |
| Completed | N/A | 75 | Europe | Clinical assessment, Ecological evaluation, Neuropsychological evaluation, Psychological evaluation, MRI Evaluation | University Hospital, Bordeaux, Genzyme, a Sanofi Company | Multiple Sclerosis, Relapsing-Remitting | 02/23 | 02/23 | | |
NCT03198351: An Observational Study on Teriflunomide-exposed Pregnancies |
|
|
| Completed | N/A | 220 | Canada, US | Teriflunomide (HMR1726), Aubagio | Sanofi | Multiple Sclerosis | 06/23 | 06/23 | | |
DOT-MS, NCT04260711: Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (). |
|
|
| Recruiting | N/A | 130 | Europe | DMT, Interferon, Glatiramer acetate, Dimethylfumarate, Teriflunomide | VU University Medical Center | Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive | 08/23 | 01/24 | | |
TERIPET, NCT03368677: Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression |
|
|
| Active, not recruiting | N/A | 26 | Europe | | Turku University Hospital | Multiple Sclerosis | 12/24 | 12/24 | | |
NCT03399981: Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries |
|
|
| Completed | N/A | 80327 | US | Tysabri, Natalizumab BG00002 | Biogen | Progressive Multifocal Leukoencephalopathy | 12/23 | 12/23 | | |
| Completed | N/A | 10 | Europe | Brain MRI (3T, 7T, 9.4T) | Zuyderland Medisch Centrum, Scannexus | Multiple Sclerosis | 06/24 | 06/24 | | |
FILAXOS, NCT06551519: A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis |
|
|
| Recruiting | N/A | 900 | Europe | ofatumumab, DMT category 1 | Novartis Pharmaceuticals | Multiple Sclerosis | 09/27 | 09/27 | | |
| Completed | N/A | 100 | Europe | Blood sample | Centre Hospitalier Régional d'Orléans | Healthy, Multiple Sclerosis | 07/24 | 07/24 | | |
| Recruiting | N/A | 900 | US | Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy, Tysabri, Lemtrada, Ocrevus, Rituxan, Mavenclad, Kesimpta, Briumvi, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso | Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society | Multiple Sclerosis, Relapsing-Remitting | 08/25 | 08/25 | | |
NCT05112484: Therapeutic Monitoring of Drugs Used in the Treatment of Multiple Sclerosis |
|
|
| Not yet recruiting | N/A | 600 | RoW | Measurement of concentrations of orally-used DMDs, Genetic testing, Parameters for routine use of DMDs, Side effects of orally used DMDs | University Hospital Ostrava, University of Ostrava | Multiple Sclerosis | 11/25 | 05/26 | | |
| Enrolling by invitation | N/A | 323 | RoW | Cladribine, Mavenclad, Dimethyl fumarate, Tecfidera, Fingolimod, Gilenya, Teriflunomide, Aubagio, Ozanimod, Zeposia, Diroximel fumarate, Vumerity | Monash University | Multiple Sclerosis, Adherence, Medication | 11/25 | 07/26 | | |
KRONOS, NCT05776888: Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years |
|
|
| Recruiting | N/A | 100 | Europe | Ofatumumab | Novartis Pharmaceuticals | Relapsing Multiple Sclerosis | 08/26 | 08/26 | | |
PROMISE, NCT05962177: Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic |
|
|
| Recruiting | N/A | 400 | Europe | Magnetic Resonance Imaging, Blood withdrawal, Neuropsychological tests | University Hospital, Montpellier | Multiple Sclerosis | 07/28 | 07/28 | | |
NCT05767736: A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS) |
|
|
| Active, not recruiting | N/A | 10500 | US | Diroximel Fumarate, VUMERITY, BIIB098, Dimethyl Fumarate, Tecfidera, DMF, BG00012, Disease-Modifying Therapies (DMTs) | Biogen | Multiple Sclerosis | 12/32 | 12/32 | | |
| Recruiting | N/A | 900 | RoW | SAR442168 | Peking University Third Hospital | Relapsing Multiple Sclerosis | 08/21 | 08/24 | | |
DATE-TCM, NCT05415579: Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine |
|
|
| Not yet recruiting | N/A | 2000 | NA | Traditional Chinese medicine (TCM) | Dongzhimen Hospital, Beijing | Demyelinating Diseases of the Central Nervous System (DDC) | 10/29 | 05/30 | | |
